Diurnal is focused on developing and commercialising rare disease therapies in the area of endocrinological diseases. We have a growing product pipeline, with multiple candidates in development.
- About Us
About Us
Founded in 2004, DIURNAL® , a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.
- Research
Research
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
- Partnering
Partnering
Partnering and business development is integral to our strategy of building a leading pharmaceutical company. We forge creative partnerships with other innovative companies that advance our business.
- Investors
Investors
Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc
- PR Archive
PR Archive
View all historical press releases in the News section. Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc.
- Transparency
- Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision.